Received Aug 4, 2025
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| MMR | MEASLES + MUMPS + RUBELLA (MMR II) | MERCK & CO. INC. | UNK | — | — |
No additional AE; HCP called regarding spacing of ROTATEQ and MMR II. HCP had a 6 month and 21 day old patient in the office who received MMR II on 7/1/2025 and requested information on administering ROTATEQ today, 7/10/2025. See request case 02836659. No additiona; This spontaneous report was received from a medical assistant and refers to a 6-month-old patient of unknown gender. The patient's medical history was not reported. The patient's concurrent conditions were not reported. Concomitant therapies were not reported. On 01-Jul-2025, the patient was vaccinated with Measles, Mumps, and Rubella (Wistar RA 27-3) Virus Vaccine, Live (M-M-R II), Powder and solvent for solution for injection (dose, route of administration, anatomical location, lot #, and expiration date were not reported) as prophylaxis. The vaccine was reconstituted with sterile diluent (lot # and expiration date were not provided) (Product administered to patient of inappropriate age). The reporter requested information on administering Rotavirus Vaccine, Live, Oral, Pentavalent (ROTATEQ) today. No additional adverse events were provided.
Sterile diluent